Log in

OTCBB:GTHPGuided Therapeutics Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume1.04 million shs
Average Volume18.71 million shs
Market Capitalization$430,000.00
P/E RatioN/A
Dividend YieldN/A
Beta0.22
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. The company focuses on marketing LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was founded in 1992 and is based in Norcross, Georgia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.68 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolOTCBB:GTHP
CUSIPN/A
Phone770-242-8723

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$240,000.00
Book Value($0.41) per share

Profitability

Net Income$-10,690,000.00
Net Margins-2,779.03%

Miscellaneous

EmployeesN/A
Outstanding Shares2,135,440,000
Market Cap$430,000.00
Next Earnings DateN/A
OptionableNot Optionable

Receive GTHP News and Ratings via Email

Sign-up to receive the latest news and ratings for GTHP and its competitors with MarketBeat's FREE daily newsletter.

Guided Therapeutics (OTCBB:GTHP) Frequently Asked Questions

How were Guided Therapeutics' earnings last quarter?

Guided Therapeutics Inc (OTCBB:GTHP) issued its quarterly earnings data on Monday, May, 21st. The medical technology company reported $0.00 EPS for the quarter. View Guided Therapeutics' earnings history.

Has Guided Therapeutics been receiving favorable news coverage?

News stories about GTHP stock have been trending neutral this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Guided Therapeutics earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the medical technology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Guided Therapeutics.

Who are some of Guided Therapeutics' key competitors?

What other stocks do shareholders of Guided Therapeutics own?

Who are Guided Therapeutics' key executives?

Guided Therapeutics' management team includes the following people:
  • Mr. Gene S. Cartwright Ph.D., Chief Exec. Officer, Pres, Acting Chief Financial Officer and Director (Age 64)
  • Dr. Mark L. Faupel, COO & Director (Age 63)
  • Mr. Richard L. Fowler, Sr. VP of Engineering and Sec. (Age 62)
  • Mr. Charles Rufai, Controller

What is Guided Therapeutics' stock symbol?

Guided Therapeutics trades on the OTCBB under the ticker symbol "GTHP."

How do I buy shares of Guided Therapeutics?

Shares of GTHP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Guided Therapeutics?

Guided Therapeutics has a market capitalization of $0.00 and generates $240,000.00 in revenue each year.

What is Guided Therapeutics' official website?

The official website for Guided Therapeutics is www.guidedinc.com.

How can I contact Guided Therapeutics?

Guided Therapeutics' mailing address is 5835 PEACHTREE CORNERS EAST SUITE D, NORCROSS GA, 30092. The medical technology company can be reached via phone at 770-242-8723 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.